The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 11, 2010

Filed:

Nov. 20, 2007
Applicants:

Christian Gege, Ehingen, DE;

Matthias Schneider, Dossenheim, DE;

Carine Chevrier, Ramonchamp, FR;

Hongbo Deng, Southborough, MA (US);

Irving Sucholeiki, Winchester, MA (US);

Brian M. Gallagher, Jr., Merrimac, MA (US);

Michael Bosies, Weinheim, DE;

Christoph Steeneck, Dossenheim, DE;

Xinyuan Wu, Newton, MA (US);

Matthias Hochgürtel, Schriesheim, DE;

Bert Nolte, Aachen, DE;

Arthur Taveras, Southborough, MA (US);

Inventors:

Christian Gege, Ehingen, DE;

Matthias Schneider, Dossenheim, DE;

Carine Chevrier, Ramonchamp, FR;

Hongbo Deng, Southborough, MA (US);

Irving Sucholeiki, Winchester, MA (US);

Brian M. Gallagher, Jr., Merrimac, MA (US);

Michael Bosies, Weinheim, DE;

Christoph Steeneck, Dossenheim, DE;

Xinyuan Wu, Newton, MA (US);

Matthias Hochgürtel, Schriesheim, DE;

Bert Nolte, Aachen, DE;

Arthur Taveras, Southborough, MA (US);

Assignee:

Alantos Pharmaceuticals Holding, Inc., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/535 (2006.01); C07D 265/12 (2006.01); C07D 413/00 (2006.01); A01N 43/00 (2006.01); A01N 43/46 (2006.01); A61K 31/553 (2006.01); A61K 31/554 (2006.01); A61K 31/55 (2006.01); A61K 31/54 (2006.01); C07D 498/00 (2006.01); C07D 291/08 (2006.01); C07D 281/02 (2006.01); C07D 267/02 (2006.01); C07D 223/16 (2006.01); C07D 513/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.


Find Patent Forward Citations

Loading…